Research.Patient.info
Relapsed/Refractory Follicular Lymphoma research hub
2 indexed studies · 1 currently recruiting
- active not recruitingPHASE3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
This study is for adults with a type of blood cancer called follicular lymphoma, which has come back or isn't responding to treatment. It compares a new drug (Tazemetostat) with existing treatments to see if it's safe and helps people live longer without their cancer getting worse.
United States · Australia · Belgium - recruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
United Kingdom